


## Category

Dual GIP/GLP-1\* receptor agonist

## Dosing

## Dosage Forms

PFS<sup>+</sup> in Physioject (auto-injector) 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg



After reaching the **5 mg** dose, the weekly dose **may** be increased by **2.5 mg every 4 weeks**, up to a **maximum of 15 mg**, based on response and tolerability. If patients do not tolerate a maintenance dose, consider a lower one.

## Indications



**Treatment of type 2 diabetes mellitus**



**Weight management**

In adults with obesity, or overweight in the presence of  $\geq 1$  weight-related comorbid condition



**Obstructive sleep apnea, moderate to severe**

In adults with obesity

## Effectiveness for Weight Loss

Overall percentage change in body weight from baseline at 72 weeks



**-20.9%**  
tirzepatide 15 mg

**-19.5%**  
tirzepatide 10 mg

**-15%**  
tirzepatide 5 mg

~ 1 in 3 people taking tirzepatide 10 mg or 15 mg experienced

**25%**  
weight loss

**91%**

of adults taking tirzepatide 15 mg achieved weight loss of  $\geq 5\%$  at 72 weeks.

\*glucose-dependent insulintropic polypeptide/ glucagon-like peptide-1

<sup>+</sup>Pre-filled syringe

## Effectiveness in Type 2 Diabetes



Up to **-2.3%** by tirzepatide 15 mg

Up to **-2.2%** by tirzepatide 10 mg

Up to **-2%** by tirzepatide 5 mg

Percentage of patients with A1C <7%

**86%**

15 mg

**86%**

10 mg

**82%**

5 mg



Sustained A1C and weight reduction in patients with type 2 diabetes throughout clinical trials

## Considerations

### Contraindications

- Personal or family history of medullary thyroid carcinoma
- Patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)



### Tips for the management of gastrointestinal adverse reactions

- Ensure adequate hydration.
- Choose easily digestible foods, avoid gastric irritants (such as spices and alcohol).
- Titrate the dose slowly.
- Consider temporary use of symptom-relief medications during dose escalation.

Package Leaflet and  
References

